It is thought that only certain patients are eligible for immunotherapy: those presenting with either high expression levels of CTLA-4 and PD-1 receptor ligands on cancer/stromal cells, or increased amounts of the immune checkpoint inhibitor receptors on immune cells. Here, CTLA4 is linked to cancer.